Elucid
Elucid is a pioneering medical technology company focused on improving cardiovascular diagnostics through its FDA-cleared Plaque IQ™ software. This innovative, non-invasive imaging analysis tool utilizes advanced algorithms and histological validation to assess arterial plaque stability and composition, enabling personalized treatment plans and better patient outcomes. With a strong foundation in clinical research and partnerships with healthcare providers, Elucid aims to enhance diagnostic accuracy and reduce unnecessary invasive procedures, positioning itself as a leader in the cardiovascular imaging market.
Elucid
Elucid is a pioneering medical technology company focused on improving cardiovascular diagnostics through its FDA-cleared Plaque IQ™ software. This innovative, non-invasive imaging analysis tool utilizes advanced algorithms and histological validation to assess arterial plaque stability and composition, enabling personalized treatment plans and better patient outcomes. With a strong foundation in clinical research and partnerships with healthcare providers, Elucid aims to enhance diagnostic accuracy and reduce unnecessary invasive procedures, positioning itself as a leader in the cardiovascular imaging market.
TL;DR
Flagship product: PlaqueIQ — FDA-cleared CTA-based plaque analysis that quantifies and classifies atherosclerotic plaque validated against ground-truth histology
Company focus: Boston-based AI medical technology company focused on cardiovascular/atherosclerosis imaging and non-invasive plaque assessment
Recent financing: Series C $80M announced Nov 9, 2023 (led by Elevage Medical Technologies); total funding reported at $121M
Headcount: 122 employees
Company Overview
Problem Domain
Atherosclerosis assessment and cardiovascular imaging—non-invasive quantification of plaque morphology, composition, and lesion-specific ischemia.
Founded
2013
Industry
AI medical technology
Funding Track Record
8,000,000 USD
Participating investors included Checkmate Capital, IAG Capital, BlueStone Venture Partners, University of Michigan – Wolverine Venture Fund, Willamette Valley Capital LLC, and Angel Physicians Fund.
27,000,000 USD
Participating investors included Biovision Ventures and existing investors such as MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners.
80,000,000 USD
Company stated this round brought total funding to $121M since inception.
Investor Signal
“Series C led by Elevage Medical Technologies; prior and participating investors include MedTex Ventures, Global Health Impact Fund, IAG Capital, BlueStone Venture Partners, Biovision Ventures, and Bold Brain Ventures.”